Q1 2023 Results

Company overview Financial review Conclusions Innovation: Pipeline overview Financial performance Cardiovascular Immunology LeqvioⓇ - siRNA (regulation of LDL-C) NCT04652726 ORION-16 (CKJX839C12301) Appendix Innovation: Clinical trials Neuroscience Oncology References Leqvio® - siRNA (regulation of LDL-C) NCT04659863 ORION-13 (CKJX839C12302) Hyperlipidemia, pediatrics Indication Hyperlipidemia, pediatrics Indication Phase Phase 3 Phase Phase 3 Patients 141 Patients 13 Primary Outcome Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 Measures Primary Outcome Measures Arms Intervention Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630 Arms Intervention Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol Target Patients (LDL-C) Readout Milestone(s) 2025 Abbreviations Other Target Patients Readout Milestone(s) Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630. Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C) 2025 Design publication (O-16/-13) in Eur. J. Prev. Cardiol. Vol. 29, Feb. 2022 (actual) Presentation at EAS May-2022 on O-13/-16 study design (actual) Publication Design publication (O-16/-13) in Eur. J. Prev. Cardiol. Vol. 29, Feb. 2022 (actual) Publication Presentation at EAS May-2022 on O-13/-16 study design (actual) 49 Investor Relations | Q1 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation